Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 558

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

Open access
Barkal, Amira A., Weiskopf, Kipp, Kao, Kevin S., Gordon, Sydney R., Rosental, Benyamin, Yiu, Ying Y., George, Benson M., Markovic, Maxim, Ring, Nan G., Tsai, Jonathan M., McKenna, Kelly M., Ho, Po Yi, Cheng, Robin Z., Chen, James Y., Barkal, Layla J., Ring, Aaron M., Weissman, Irving L., Maute, Roy L.·2018·Nature Immunology

Abstract

Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need for basic studies of immunoregulation in both adaptive cell lineages and innate cell lineages. Here we found a central role for major histocompatibility complex (MHC) class I in controlling the phagocytic function of macrophages. Our results demonstrated that expression of the common MHC class I component β2-microglobulin (β2M) by cancer cells directly protected them from phagocytosis. We further showed that this protection was mediated by the inhibitory receptor LILRB1, whose expression was upregulated on the surface of macrophages, including tumor-associated macrophages. Disruption of either MHC class I or LILRB1 potentiated phagocytosis of tumor cells both in vitro and in vivo, which defines the MHC class I–LILRB1 signaling axis as an important regulator of the effector function of innate immune cells, a potential biomarker for therapeutic response to agents directed against the signal-regulatory protein CD47 and a potential target of anti-cancer immunotherapy. Host cells display ‘don’t eat me’ signals to protect themselves from phagocytosis. Maute and colleagues identify a novel ‘don’t eat me’ system based on recognition of MHC class I by the phagocyte-expressed inhibitory molecule LILRB1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41590-017-0004-z

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 558

Metadata

Authors
Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., George, B. M., Markovic, M., Ring, N. G., Tsai, J. M., McKenna, K. M., Ho, P. Y., Cheng, R. Z., Chen, J. Y., Barkal, L. J., Ring, A. M., Weissman, I. L., & Maute, R. L.
Venue
Nature Immunology
Published
2017-11-27
Volume
19
Issue
1
Pages
76-84
ISSN
  • 1529-2908 (ISSN-L)
  • 1529-2916
OpenAlex
W2768892314
Cited by
558
References
42
FWCI
11.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41590-017-0004-z
The paper
Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., George, B. M., Markovic, M., Ring, N. G., Tsai, J. M., McKenna, K. M., Ho, P. Y., Cheng, R. Z., Chen, J. Y., Barkal, L. J., Ring, A. M., Weissman, I. L., & Maute, R. L. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. https://doi.org/10.1038/s41590-017-0004-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.